Meeting Banner
Abstract #0319

Gd-EOB-DTPA-enhanced MRI in Nonalcoholic Steatohepatitis (NASH): Liver Fibrosis or Liver Function?

Iris Y. Zhou1, Chuantao Tu2, Veronica Clavijo Jordan1, Nicholas J. Rotile1, Mozhdeh Sojoodi3, Bryan C. Fuchs3, Kenneth K. Tanabe3, and Peter Caravan1
1Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging (i3), Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United States, 2Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China, 3Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States

Nonalcoholic steatohepatitis (NASH) promotes fibrotic remodeling of the liver parenchyma, which may lead to cirrhosis, liver failure, or hepatocellular carcinoma. Gd-EOB-DTPA is a hepatobiliary T1 MRI contrast agent, receiving increasing attention as a tool for detecting and staging liver fibrosis. Here, using a choline-deficient high-fat diet (CDAHFD) for different durations we modeled NASH disease progression in rats and performed Gd-EOB-DTPA-enhanced MRI at different disease stages, correlating imaging histological measures of fibrosis as well as liver function tests. Gd-EOB-DTPA-enhanced MRI correlated well with liver function tests but not with liver fibrosis.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here